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Abstract Coagulase-negative staphylococci (CoNS) are the
most frequently isolated bacteria from the blood and the pre-
dominant cause of nosocomial infections. Macrolides,
lincosamides and streptogramin B (MLSB) antibiotics, espe-
cially erythromycin and clindamycin, are important therapeu-
tic agents in the treatment of methicillin-resistant staphylococ-
ci infections. Among CoNS, Staphylococcus hominis repre-
sents the third most common organism. In spite of its clinical
significance, very little is known about its mechanisms of
resistance to antibiotics, especially MLSB. Fifty-five
S. hominis isolates from the blood and the surgical wounds
of hospitalized patients were studied. The erm(C) gene was
predominant in erythromycin-resistant S. hominis isolates.
The methylase genes, erm(A) and erm(B), were present in
15 and 25 % of clinical isolates, respectively. A combination
of various erythromycin resistance methylase (erm) genes was
detected in 15 % S. hominis isolates. The efflux gene msr(A)
was detected in 18 % of isolates, alone in four isolates, and in
different combinations in a further six. The lnu(A) gene, re-
sponsible for enzymatic inactivation of lincosamides was car-
ried by 31 % of the isolates. No erythromycin resistance that
could not be attributed to the genes erm(A), erm(B), erm(C)
and msr(A) was detected. In S. hominis, 75 and 84 %, respec-
tively, were erythromycin resistant and clindamycin suscepti-
ble. Among erythromycin-resistant S. hominis isolates, 68 %
of these strains showed the inducible MLSB phenotype. Four
isolates harbouring themsr(A) genes alone displayed theMSB
phenotype. These studies indicated that resistance to MLSB in
S. hominis is mostly based on the ribosomal target modifica-
tion mechanism mediated by erm genes, mainly the erm(C),
and enzymatic drug inactivation mediated by lnu(A).
Introduction
Coagulase-negative staphylococci (CoNS) are part of the
normal bacterial flora of human skin, but they have been
increasingly recognized as opportunistic pathogens capable
of causing various types of infections (Piette and
Verschraegen 2009). Among clinically significant strains
of CoNS, Staphylococcus hominis is ranked the third in
importance only after S. epidermidis and S. haemolyticus.
The S. hominis is a genetically diverse species, and it is
believed that recombination plays a significant role in gen-
erating this diversity (Mendoza-Olazarán et al. 2013;
Zhang et al. 2013; Szczuka et al. 2014). These bacteria
can be responsible for blood stream infections, endocardi-
tis, peritonitis, bone and joint infections (Kloos and
Bannerman 1999; Kaufman and Fairchild 2004; Chaves
et al. 2005; Sorlozano et al. 2010; Bouchami et al.
2011). Similar to other staphylococci, the formation of
biofilm on medical devices, or on host tissues, is thought
to be the one of the major pathogenic factors of S. hominis
(Kaufman and Fairchild 2004; Götz et al. 2006; Chokr et al.
2006; Rodhe et al. 2006; Fredheim et al. 2009; Szczuka
et al. 2015). Relatively high prevalence of methicillin re-
sistance complicated the treatment of staphylococcal
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infections (Casey et al. 2007). Macrolides, lincosamides
and streptogramin B antibiotics are the preferred alterna-
tive to penicillins and cefalosporins in the treatment of
staphylococci infection. Moreover, erythromycin and
clindamycin are recommended as second-line drugs for
patients with a β-lactam allergy (Leclercq 2002; Gherardi
et al. 2009). MLSB antibiotics are structurally distinct but
functionally similar because they inhibit protein synthesis
by binding to the 50S subunit (23S rRNA) of the bacterial
ribosome. In staphylococci, resistance to MLSB is gener-
ally based on three mechanisms: the ribosomal target mod-
ification mediated by erm genes, the active efflux of anti-
biotics mediated by msr(A) and enzymatic drug inactiva-
tion mediated by lnu(A) (Leclercq 2002). The lnu(A) gene
encodes lincosamide O-nucleotidyltransferase, which only
inactivates lincosamides. Erythromycin-resistance methylase
(erm) genes encode proteins which methylate adenine residue
A2058 in the peptidyltransferase region of 23S rRNA domain
V, which is part of the large (50S) ribosomal subunit and
prevents the binding of the antibiotic to the target site
(Leclercq 2002; Novotna et al. 2005). This methylation results
in cross-resistance to macrolide, lincosamide and
streptogramin B antibiotics (MLSB phenotype), which can
be expressed either constitutively (cMLSB) or inducibly
(iMLSB). Coagulase-negative staphylococci, with an iMLSB
resistance phenotype are resistant to 14-membered and
15-membered macrolides, whereas CoNS with a cMLSB
resistance phenotype are resistant to all MLSB antimicrobials.
Themsr(A) gene is involved in the active efflux of antibiotics,
causing resistance to 14- and 15-membered macrolides as well
as to streptogramin, but not to lincosamides (MSB phenotype).
This makes clindamycin, as a treatment choice, effective (Lina
et al. 1999; Leclercq 2002; Vimberg et al. 2015).
The main purpose of this study was to assess the molecular




Fifty-five isolates of S. hominis were collected from the blood
and surgical wound swabs of hospitalized patients. True bac-
teremia was diagnosed in 36 the of patients. The isolates were
identified by using the VITEK 2 system (bioMérieux, France).
Although the tuf sequencing gives perfect results in the iden-
tification of this species, the VITEK 2 offers very good results
as well. Because the S. hominis is a genetically diverse spe-
cies, we confirmed the identification of all tested S. hominis
isolates by using the API STAPH. In this study, we included
only those isolates whose identification was beyond any
doubt. The isolates were stored at −70 °C, in 50 % glycerol
broth (BHI), until commencement of the study.
Characterization of resistance mechanisms
Phenotypic characterization of macrolides and lincosamides
resistance was determined by the double-disc test, with eryth-
romycin (15 μg) and clindamycin (2 μg) discs applied 20 mm
apart. A 10-μl inoculum of a 0.5 McFarland suspension was
spotted onMueller-Hinton agar with antibiotic disc. After 18 h
incubation at 35 °C, blunting of the clindamycin zone of in-
hibition proximal to the erythromycin disc indicated the in-
ducible type (D-shaped zone) of MLSB resistance, whereas
resistance to both erythromycin and clindamycin indicated
the constitutive type. Lack of a D-shaped zone in
erythromycin-resistant and clindamycin-susceptible isolates
was interpreted as the MSB efflux phenotype (Leclercq
2002; Aktas et al. 2007). The results were interpreted accord-
ing to EUCAST recommendations. Isolates were also
screened with a 30-μg cefoxitin disc and studied for the pres-
ence of mecA genes to test methicillin resistance (Geha et al.
1994). The bacterial genomic DNAwas isolated from clinical
isolates using the Genomic DNA Plus kit (A&A Biotechnol-
ogy, Poland). For the detection of macrolide resistance genes
(erm(A), erm(B), erm(C), msr(A), lun(A)) and mecA genes,
PCR assays were performed as described by Lina et al. (1999),
Le Bouter et al. (2011) and Geha et al. (1994). The
STATISTICA software (10.00 StatSoft, Tulsa, OK, USA)
was used for statistic analysis. Association between methicil-
lin resistance and resistance to MLSB antibiotics was evaluat-
ed by using chi-square (χ2) test. A P value of <0.05 was
considered significant.
Results
The most prevalent resistance determinant was erm(C) which
was detected in 25 of the isolates (45 %), followed by lnu(A),
erm(B) and erm(A) detected in 17 (31 %), 14 (25 %) and 8
(15 %) isolates, respectively. The msr(A) gene was detected
alone, in 4 isolates and in 6 isolates, in combination with other
genes. As Table 1 shows, 14 distinct resistance genotypes
could be observed in the S. hominis strains. Fourteen isolates
were negative for all screened genes.
All isolates harbouring the erm(B) or erm(C) genes alone
or in combination with other genes exhibited resistance to
erythromycin. The erm(A) was never found alone and all
erm(A)-positive isolates were resistant to erythromycin. Four-
teen isolates, which were negative for all five resistance genes,
displayed susceptibility to erythromycin and clindamycin. No
isolates, resistant to clindamycin only, were found. Twenty
eight erm-positive isolates were resistant to erythromycin
but remained susceptible to clindamycin and exhibited the
144 Folia Microbiol (2016) 61:143–147
inducible MLSB phenotype. The remaining nine erm-positive
isolates showed resistance to erythromycin and clindamycin,
displaying the constitutive MLSB phenotype. It should be em-
phasized that the cMLSB phenotype was detected only in
strains harbouring simultaneously erm and lnu(A). The four
isolates, harbouring themrsA gene alone, represented theMSB
phenotype. Methicillin-resistant S. hominis isolates were sig-
nificantly more often resistant to macrolides and lincosamides
(93% to erythromycin, 77% to clindamycin) than methicillin-
susceptible isolates (50 and 22 %, respectively; p<0.001).
Discussion
Coagulase-negative staphylococci have been recognized as
an important cause of nosocomial infections and are the
most frequently isolated bacteria from blood (Krediet
et al. 2004; Hira et al. 2007; Piette and Verschraegen
2009). These pathogens have developed an increased resis-
tance to antimicrobial agents, especially to methicillin and
other semisynthet ic penic i l l ins . Among CoNS,
S. haemolyticus has the highest tendency to develop resis-
tance to multiple antibiotics (Rodríguez-Aranda et al.
2009). S. hominis isolates display a lower virulence than
S. haemolyticus and have been recognized, less frequently,
as significant human pathogens. However, there are reports
indicating that S. hominis can be responsible for nosocomi-
al outbreaks (Chaves et al. 2005; d’Azevedo et al. 2008;
Palazzo et al. 2008; Sorlozano et al. 2010; Ruiz de
Gopegui et al. 2011; Roy et al. 2014). Nevertheless, there
is limited information on their resistance to antibiotics, es-
pecially to macrolides, lincosamides and streptogramin B.
As mentioned above, MLSB are used against staphylococ-
cal infection in penicillin-allergic patients and in
methicillin-resistant staphylococci (MRS)-infected patients.
In particular, the use of clindamycin is regarded as a valid
choice in the treatment of soft-tissue and bone infections
(Lina et al. 1999; Leclercq 2002; Gherardi et al. 2009). The
present data indicates that 16 % of S. hominis strains were
resistant to clindamycin, whereas 75 % displayed resistance
to erythromycin. In German studies, only 19 % of
S. hominis strains were erythromycin resistant (Gatermann
et al. 2007). Most of these strains displayed the constitutive
MLSB phenotype, as opposed to our study, which demon-
strated that the majority of S. hominis expressed the induc-
ible MLSB phenotype. It should be emphasized, that
coagulase-negative staphylococci, with an iMLSB resistance
phenotype are resistant to 14-membered and 15-membered
macrolides, but susceptible to lincosamides, streptogramin
B and 16-membered macrolides. Although, iMLSB CoNS
are in vitro resistant to erythromycin and in vitro sensitive
to clindamycin, prescribing clindamycin may lead to treat-
ment failure. In our studies, more than half of the S. hominis
isolates were resistant to methicillin. Additionally, methicil-
lin resistance was closely associated with resistance to
erythromycin, which narrows the therapeutic options. It is
well known that glycopeptides are the treatment of choice
for infections caused by the multi-resistant staphylococci.
However, due to the emergence of vancomycin-resistant
staphylococci, a reduction in the use of this antibiotic has
Table 1 Distribution of
resistance genes ermA, ermB,
ermC, msrA and linA among
S. hominis clinical strains
Resistance genotype No. of isolates No. of isolates with phenotype
MLSB—inducible MLSB—constitutive MSB
ermB 1 1 0 0
ermC 9 9 0 0
msrA 4 0 0 4
ermA+ ermB 3 3 0 0
ermA+ ermB+ ermC 2 2 0 0
ermB+ msrA 2 2 0 0
ermC+ msrA 2 2 0 0
ermA+ lnu(A) 1 0 1 0
ermB+ lnu(A) 2 0 2 0
ermC+ lnu(A) 10 5 5 0
ermA+ ermB+ lnu(A) 2 1 1 0
ermB+ ermC+ lnu(A) 1 1 0 0
ermB+ msrA+ lnu(A) 1 1 0 0
ermC+ msrA+ lnu(A) 1 1 0 0
No gene 14 0 0 0
Total 55 28 9 4
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been recommended. Recently, Won and Kim (2013) has
reported the emergence of vancomycin-resistant S. hominis.
Also, the emergence of resistance to relatively new antibi-
otics, such as linezolid and quinupristin/dalfopristin, has
also been noted, in clinical S. hominis strains (Petinaki
et al. 2005; Ruiz de Gopegui et al. 2011).
This study indicated that the resistance to macrolides
and lincosamides in S. hominis is mostly based on the
ribosomal target modification mechanism mediated by
erm genes; mainly the erm(C) and enzymatic drug inac-
tivation, mediated by lnu(A). The erm(C) genes are pre-
dominant among coagulase-negative staphylococci from
European countries, Canada and Korea (Martineau et al.
2000; Lim et al. 2002; Novotna et al. 2005; Gatermann
et al. 2007; Gherardi et al. 2009). However, these data
largely concerns the most frequently isolated coagulase-
negative strains i.e. S. epidermidis and S. haemolyticus,
whereas little is known about the distribution of MLSB
resistance genes in other staphylococci species, including
S. hominis. Recently, Le Bouter et al. (2011) character-
ized resistance to macrolides, l incosamides and
streptogramin B in 72 S. saprophyticus strains isolated
from urine specimens. They found that the distribution
of MLSB resistance genes in S. saprophyticus is different
from that generally reported for S. epidermidis and
S. haemolyticus. The results of this study show that
erm(A) and erm(B) genes were present more frequently
in S. hominis than in other staphylococcal species as
previously described (Martineau et al. 2000; Gatermann
et al. 2007; Gherardi et al. 2009). For example, in a
study conducted in Korea, erm(B) genes were present
only in 3.3 % of isolates (Lim et al. 2002). The efflux
of macrolides due to msr(A) is a mechanism found only
in a minority of S. hominis. Previously obtained data
indicates that msr(A) genes were present in 11–24 % of
coagulase-negative staphylococci (Aktas et al. 2007;
Bouchami et al. 2007; Gatermann et al. 2007). In con-
trast, in S. saprophyticus, the efflux mechanisms were
the most common mechanisms of resistance to MLSB
antibiotics (Le Bouter et al. 2011). We observed a high
occurrence of the lnu(A) gene, which confer resistance to
lincomycin, but clindamycin remains active (Leclercq
2002). Overall, this study suggested that S. hominis
may constitute a reservoir for MLSB genes, in particular
erm(C) and lnu(A), among coagulase-negative staphylo-
cocci. These resistance genes are often located on plas-
mids or transposons and may be transferable to more
pathogenic staphylococcal species (Leclercq 2002).
Our results indicated that the uncommon pathogen,
S. hominis had a high prevalence of erythromycin resistance
and most of these strains display the inducible MLSB pheno-
type. Ribosomal modification and drug inactivation are the
main mechanisms of MLSB resistance, in S. hominis strains.
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